Di-aryl-substituted-ethane pyridone pde4 inhibitors
CA 2490097 A1 · Owner: Merck Frosst Canada Ltd. · Inventors: Martins, Evelyn; Cote, Bernard
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Di-aryl substituted ethane pyridones, particularly ethane pyridones substituted with i) a phenyl, ii) a pyridyl iii) a thiazole, iv) a , pyrimidinyl, v) a pyridazinyl vi) a furyl, vii) a thienyl, viii) an oxazolyl ix) an isoxazolyl, or x) an isothiazolyl moiety are phosphodiesterase-4 inhibitors useful in the treatment or prevention of asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult respiratory distress syndrome; ulcerative colitis; Crohn's disease; hypersecretion of gastric acid; bacterial fungal or , viral induced sepsis or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.